Admission to trading on the NEX Exchange Growth Market
The Company has raised a total of
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner within 12-18 months.
The Company originated from the
The majority of conventional cancer treatments (other than surgery) on the market are chemotherapy or radiotherapy based. These are non-selective by nature and highly toxic to healthy tissue as well as tumours. Accordingly, treatment can only be delivered in carefully controlled doses over a limited period of time. To address this problem directly, the Company has developed sophisticated formulation and prodrug targeting technologies to deliver treatment specifically to the tumour. Prodrugs are chemically modified versions of pharmacologically active agents which only become active when they reach a target, thus reducing generalised toxicity in normal tissues, whilst enabling higher doses to reach a target and therefore increase efficacy.
The Company is admitted to the NEX Exchange Growth Market today, having raised
Commenting on the Admission to NEX,
"We are delighted with our admission to the NEX Exchange Growth Market today.
Cancer is one of the world's most pressing health challenges. There is a clear unmet clinical need for developing targeted oncology medicines that are effective against tumours whilst avoiding harsh systemic side effects and we believe that our unique strategy offers one of the most promising approaches.
This public listing on NEX will provide an excellent platform for further growth, through awareness and further progression of our existing technologies.
We are particularly excited by the near-term licensing and commercialisation opportunity of our near to market product, Sol, which now will become the focus of our near-term efforts.
We look forward to updating the market with our progress in due course."
The Directors of the Company accept responsibility for the content of this announcement.
For further information, please contact:
Simon Ward, Chief Executive Officer +44 (0) 7747 625506
Suzanne Brocks, Head of Communications +44 (0) 7776 234600
NEX Exchange Corporate Adviser:
Jo Turner / James Lewis +44 (0) 20 7213 0880
Patrick Claridge / John Howes / Bob Pountney +44 (0) 20 3815 8880
This information is provided by RNS, the news service of the